drugset / Trial / NCT01461447
Safety Study of an Additional MVA Vaccine in Volunteers Who Received 3 DNA Vaccines Followed by 2 MVA Vaccines
Phase 1/2
Completed
20 enrolled
Muhimbili University of Health and Allied Sciences
Karolinska Institutet · collabSwedish Institute for Infectious Disease Control · collabWalter Reed Army Institute of Research (WRAIR) · collab
NaSingle-groupOpen-label
Summary
The purpose of the study is to determine the safety and immunogenecity of a third MVA in the HIVIS 03 volunteers who have received 3 HIVIS DNA vaccines followed by boosting with 2 MVA vaccines. The investigators postulate that the Immune responses that were observed in the HIVIS 03 trial are likely to wane over time. To date it is unknown how these responses should best be maintained. In this study the investigators seek to boost immune responses, especially the antibody responses induced by the second MVA boost. Since the HIV specific antibodies were induced only after the second MVA injection, it is hypothesized that a 3rd MVA will give rise to even higher and sustained antibody titers.
Timeline
- Start
- 2012-03
- Primary completion
- 2012-05
- Completion
- 2012-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMVAMUNE | Vaccine | 1 ml | Intramuscular |
| Subject | IMVAMUNE | Vaccine | 1e+08 unknown | Intramuscular |
Indications
No indication recorded.